{
    "ticker": "NCRA",
    "name": "Neurocrine Biosciences, Inc.",
    "description": "Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine disorders. Founded in 1992 and headquartered in San Diego, California, Neurocrine aims to improve the lives of patients through its commitment to scientific research and the development of new therapies. The company's lead product, Ingrezza (valbenazine), is the first FDA-approved treatment for tardive dyskinesia, a serious movement disorder caused by long-term use of antipsychotic medications. In addition to Ingrezza, Neurocrine is advancing a robust pipeline of product candidates targeting conditions such as Parkinson's disease, epilepsy, and endometriosis. Neurocrine's research efforts leverage advanced technologies and collaborations with leading academic institutions, ensuring a strong focus on unmet medical needs. The company\u2019s mission is to deliver meaningful therapies that make a difference in the lives of those affected by these challenging conditions, reflecting its dedication to patients and their families.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "1992",
    "website": "https://www.neurocrine.com",
    "ceo": "Kevin Gorman",
    "social_media": {
        "twitter": "https://twitter.com/Neurocrine",
        "linkedin": "https://www.linkedin.com/company/neurocrine-biosciences"
    },
    "investor_relations": "https://investors.neurocrine.com",
    "key_executives": [
        {
            "name": "Kevin Gorman",
            "position": "CEO"
        },
        {
            "name": "Matt Abernethy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Products",
            "products": [
                "Ingrezza"
            ]
        },
        {
            "category": "Pipeline Products",
            "products": [
                "NBI-827104",
                "NBI-921352"
            ]
        }
    ],
    "seo": {
        "meta_title": "Neurocrine Biosciences, Inc. | Innovative Treatments for Neurological Disorders",
        "meta_description": "Explore Neurocrine Biosciences, Inc., a leader in biopharmaceuticals focused on innovative therapies for neurological and endocrine disorders. Learn about our products and pipeline.",
        "keywords": [
            "Neurocrine",
            "Biopharmaceutical",
            "Ingrezza",
            "Neurological Disorders",
            "Endocrine Disorders"
        ]
    },
    "faq": [
        {
            "question": "What does Neurocrine Biosciences specialize in?",
            "answer": "Neurocrine Biosciences specializes in developing treatments for neurological and endocrine disorders."
        },
        {
            "question": "What is Ingrezza?",
            "answer": "Ingrezza is the first FDA-approved treatment for tardive dyskinesia."
        },
        {
            "question": "Where is Neurocrine headquartered?",
            "answer": "Neurocrine is headquartered in San Diego, California, USA."
        },
        {
            "question": "When was Neurocrine founded?",
            "answer": "Neurocrine was founded in 1992."
        }
    ],
    "competitors": [
        "VRTX",
        "INCY",
        "AMGN",
        "BIIB"
    ],
    "related_stocks": [
        "GILD",
        "CELG",
        "REGN",
        "ABBV"
    ]
}